Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Friday, September 18, 2015
On September 21, 2015, our group of companies, which presently comprises the trading companies, Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics, LSR associates and various affiliates will be rebranded as Envigo (pronounced En-vee-go...
read more
Huntingdon Life Sciences and Harlan Laboratories have announced that the combined companies will be called Envigo.
read more
Thursday, February 20, 2020
Hummingbird Bioscience has signed an agreement with Mycenax Biotech for the production of material for the Phase 1 clinical trial of its HMBD-002 program.
read more
Monday, September 18, 2017
PuraCap announced the FDA has completed a successful general inspection of its affiliated soft gelatin capsule manufacturing facility located in Wuhan, Hubei Province China.
read more
Monday, September 28, 2020
Humanigen announced a strategic collaboration with Thermo Fisher Scientific to expand the manufacturing capacity for lenzilumab, currently in a Phase 3 registration study in patients with COVID-19.
read more
Monday, November 23, 2020
Humanigen announced the company and the DoD have entered into a CRADA in collaboration with the BARDA in support of Operation Warp Speed to assist in the development of lenzilumab as a potential COVID-19 treatment.
read more
Monday, February 08, 2021
Avid Bioservices and Humanigen have entered into a manufacturing services agreement to expand production capacity for lenzilumab, Humanigen’s therapeutic candidate in development for COVID-19.
read more
Tuesday, October 12, 2021
Humanigen announced it has entered into an arrangement with Clinigen to implement a Managed Access Program for lenzilumab (“LenzMAP™”).
read more
Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s anti-human GM-CSF monoclonal antibody.
read more
Humanigen, Inc. announced it entered into an agreement with PCI Pharma Services (PCI), a integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (...
read more
Humanigen and Chime Biologics announced that they have entered into a manufacturing services agreement to produce lenzilumab bulk drug substance and drug product for Humanigen for commercial sale.
read more
Wednesday, February 09, 2022
Humanigen, Inc. and Cenexi, a French CDMO, announced a collaboration aimed at making Cenexi a preferred supplier of lenzilumab in France and the European Union. The initial step of the collaboration includes the execution of a Master Supply Agreement...
read more
Thursday, August 20, 2020
Humanetics and Pii will work together to support a clinical trial of BIO 300 in COVID-19 patients.
read more
Huma Therapeutics Limited has acquired Alcedis GmbH. Through the acquisition, Huma will form an advanced clinical trials division offering digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully...
read more
Huawei, a global information and communications technology provider, and WuXi AppTec, the global open-access R&D platform, have announced the signing of a strategic framework agreement to support the China Precision Medicine Initiative (China PMI) ...
read more